Left ventricular assist device: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Meg Taylor
No edit summary
mNo edit summary
 
Line 3: Line 3:
#[[Thoratec]] - Heartmate2 market capital $2B US
#[[Thoratec]] - Heartmate2 market capital $2B US
#[[Ventracor]] - VentrAssist
#[[Ventracor]] - VentrAssist
#[[Heartware]]
#[[Heartware]][[Category:Suggestion Bot Tag]]

Latest revision as of 06:00, 11 September 2024

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

A left ventricular assist device or LVAD is a pump which runs in parallel with a heart to boost the blood flow. The main reason for a patient to have a LVAD implanted is for bridge to transplant (BTT) or destination therapy (DT). Currently, the top three companies in this field are:

  1. Thoratec - Heartmate2 market capital $2B US
  2. Ventracor - VentrAssist
  3. Heartware